Vogelzang Law News

Environmental Protection Agency (EPA) lists asbestos as one of the 10 high-risk chemicals

December 19, 2016 By Vogelzang Law Webmaster

On December 1, 2016 the Environmental Protection Agency (EPA) listed asbestos as one of the 10 high-risk chemicals evaluated and regulated under the Lautenberg Act.  What this means is that the EPA must release a scoping document within six months which includes the hazards, exposures, conditions of use and vulnerable populations the agency plans to…

Vogelzang Law News

Mesothelioma Settlement for Wife of Union Electrician

November 15, 2016 By Vogelzang Law Webmaster

Attorney Nicholas Vogelzang settled yet another mesothelioma case for an undisclosed high dollar amount on November 8, 2016 at the Daley Center in Cook County.  His client was the wife of a union electrician out of IBEW Local 134 in Chicago.  She had laundered his clothing throughout his working career.  Most notably she shook out…

Vogelzang Law News

IVC Filters May Not Improve Mortality

November 15, 2016 By Vogelzang Law Webmaster

What does the evidence show from articles in JAMA?  In an 8 year follow up study published in 2005, 400 patients with deep vein thrombosis (DVT) considered at high risk for a pulmonary embolism were treated and studied.  All patients were anticoagulated with heparin and half of the patients received a permanent IVC filter. After…

Vogelzang Law News

Fines at U.S. Steel Plant Highlight Outsized Asbestos Threat in Allegheny County, Pa.

August 11, 2016 By Vogelzang Law Webmaster

WASHINGTON – Federal regulators have levied fines totaling $170,000 against the U.S. Steel Corporation for exposing workers to asbestos at the company’s Coke Works facility in Clairton, Pa., according the following statement the Occupational Safety and Health Administration issued Monday: During the first week of February 2016, at the company’s coke production facility in Pittsburgh, five workers…

Vogelzang Law News

UNIVERSITY OF CHICAGO MESOTHELIOMA DRUG TRIALS NEW HOPE FOR MESOTHELIOMA PATIENTS

July 29, 2016 By Vogelzang Law Webmaster

A clinical study of malignant pleural mesothelioma patients treated with investigational cancer vaccine CRS-207 at University of Chicago Medical Center, UCSF’s cancer center, the Moffitt Cancer Center in Tampa, the Abramson Cancer Center in Philadelphia and the National Cancer Institutein Bethesda, Maryland has shown promising results in shrinking tumors. CRS-207 caused tumor shrinkage in 85% of…